GRPR and prostate cancer: Our decision was triggered by positive results from previous reports in PC-3 models that highlighted the theragnostic potential of [67/68Ga/111In/177Lu]NeoBOMB1 radioligands in prostate cancer and by the excellent visualization capacity of [68Ga]NeoBOMB1 in GRPR-positive lesions in prostate cancer patients [19,20].